📗 Cite This Artifact
Recepta Biopharma
Overview
Overview
Recepta Biopharma is a Brazilian biotechnology company headquartered in São Paulo, Brazil, focused on developing antibody-based immunotherapeutics for oncology and neurodegenerative diseases. Founded in 2008, the company has expanded from its original oncology focus to include significant research and development programs targeting [neuroinflammatory pathways](/mechanisms/neuroinflammation) associated with [Alzheimer's disease](/diseases/alzheimers-disease) (AD) and [Parkinson's disease](/diseases/parkinsons-disease) (PD)[@recepta2024]. Recepta represents one of the leading biotechnology companies in Brazil's growing biopharmaceutical sector, contributing to the country's emerging strength in antibody therapeutics and neuroscience research["@brazil biotech"].
The company's mission centers on developing innovative biological therapies that address unmet medical needs in diseases with limited treatment options. Within the neuroscience domain, Recepta has established programs targeting neuroinflammation—a central pathological feature shared by both Alzheimer's and Parkinson's diseases—through novel monoclonal antibody approaches["@martins2023"]. The company's antibody engineering capabilities, developed over more than a decade of operation, provide the technological foundation for these neurodegenerative disease programs["@recepta pipeline"].
Company Background
Founding and Evolution
Recepta Biopharma was established in 2008 in São Paulo, Brazil, with an initial focus on developing antibody-based cancer therapeutics. The company's founding reflected the growing interest in Brazil's biotechnology sector during the late 2000s, as the country sought to develop domestic capabilities in innovative drug development rather than relying primarily on imported pharmaceuticals[@brazil biotech].
Since its founding, Recepta has evolved significantly:
| Attribute | Details |
|-----------|---------|
| Headquarters | São Paulo, Brazil |
| Founded | 2008 |
| Focus | Antibody therapeutics, immunotherapy |
| Stage | Clinical stage (oncology), Preclinical (neuroscience) |
| Employees | ~150 |
| Revenue | Primarily from oncology licensing |
The company's early success in oncology provided financial stability and demonstrated capability in antibody development, enabling expansion into neuroscience research programs in the mid-2010s[@recepta2024].
Brazilian Biotechnology Context
Recepta operates within Brazil's emerging biotechnology ecosystem, which has grown substantially since the company's founding. Brazil's biopharmaceutical sector has attracted increasing investment and government support, with programs like the Brazilian Industrial Biotechnology Policy encouraging development of domestic innovative drug development capabilities[@brazil biotech].
Key features of the Brazilian biotechnology environment relevant to Recepta's operations include:
- Scientific Expertise: Brazil has strong academic institutions with active neuroscience research programs, particularly in São Paulo where Recepta maintains collaborations with leading universities
- Government Support: Federal and state funding programs support biotechnology innovation, including tax incentives and direct research funding
- Growing Clinical Infrastructure: Brazil's large population provides access to diverse patient populations for clinical trials, particularly relevant for rare neurological conditions
- Regional Leadership: São Paulo has emerged as Brazil's primary biotechnology hub, with concentration of companies, research institutions, and talent
Neurodegeneration Research Programs
Recepta's neuroscience programs focus on targeting [neuroinflammation](/mechanisms/neuroinflammation), a common pathological mechanism underlying both [Alzheimer's disease](/diseases/alzheimers-disease) and [Parkinson's disease](/diseases/parkinsons-disease)[@henriquez2023]. The company leverages its antibody development expertise to create therapeutic antibodies that modulate inflammatory pathways in the central nervous system.
Alzheimer's Disease Program
Rationale
Neuroinflammation has emerged as a critical component of Alzheimer's disease pathophysiology, with mounting evidence indicating that chronic inflammatory processes contribute to disease progression[@lyman2020]. Microglia—the brain's resident immune cells—play a central role in this process, becoming persistently activated in response to amyloid-beta plaques and tau pathology. This chronic activation creates a self-perpetuating cycle of inflammation that accelerates neuronal damage[@ulrich2016].
Recepta's Alzheimer's program targets this neuroinflammatory axis through several approaches:
RGT-100 Program
The RGT-100 program represents Recepta's most advanced Alzheimer's candidate, currently in preclinical development:
| Program | Target | Stage | Indication |
|---------|--------|-------|------------|
| RGT-100 | IL-6/IL-6R | Preclinical | Alzheimer's disease |
| RGT-200 | Tau oligomers | Discovery | Alzheimer's disease |
| RGT-300 | Neuroinflammation | Discovery | Parkinson's disease |
Mechanism of Action:
RGT-100 is a monoclonal antibody designed to bind and neutralize interleukin-6 (IL-6) and its receptor (IL-6R). IL-6 is a pleiotropic cytokine that plays complex roles in brain physiology but becomes pathogenic when chronically elevated. In AD, IL-6 contributes to:
- Microglial activation and pro-inflammatory cytokine release
- Acute phase response in the brain
- Dysregulation of synaptic function
- Acceleration of amyloid processing
By neutralizing IL-6 signaling, RGT-100 could reduce neuroinflammation and potentially slow disease progression[@martins2023].
Development Status:
- Target validation completed in cellular and animal models
- Lead antibody identification and characterization
- Formulation development for intravenous administration
- IND-enabling studies in progress
RGT-200 Program
The RGT-200 program targets toxic tau oligomers, representing a complementary approach to anti-amyloid strategies:
Tau Pathology in Alzheimer's Disease:
Tau protein forms neurofibrillary tangles in Alzheimer's disease, and the spread of tau pathology correlates with cognitive decline. While tau tangles have been studied extensively, recent research indicates that soluble tau oligomers may be the most toxic species, preceding and driving the formation of insoluble tangles[@zuroff2020].
RGT-200 Approach:
- Development of antibodies that selectively recognize tau oligomers over monomeric or fibrillar tau
- Focus on conformation-specific binding to capture the toxic oligomeric form
- Potential for both therapeutic and diagnostic applications
Parkinson's Disease Program
Rationale
[Parkinson's disease](/diseases/parkinsons-disease) involves multiple pathological mechanisms, including [dopaminergic](/cell-types/dopaminergic-neurons) neuron loss, [alpha-synuclein](/proteins/alpha-synuclein) aggregation, and [neuroinflammation](/mechanisms/neuroinflammation). [Microglial activation](/cell-types/microglia) is prominent in PD brains and contributes to disease progression through release of pro-inflammatory cytokines and reactive oxygen species[@ivanova2022].
Recepta's RGT-300 program focuses on modulating neuroinflammatory pathways in Parkinson's disease, potentially complementing disease-modifying approaches targeting [alpha-synuclein](/proteins/alpha-synuclein).
RGT-300 Program
Target: Neuroinflammation in Parkinson's disease
Approach: The program aims to develop antibodies that modulate microglial activation states, shifting from the pro-inflammatory M1 phenotype toward the more beneficial M2 phenotype associated with tissue repair.
Research Status: Discovery stage, with target identification and antibody screening ongoing.
Technology Platform
Antibody Engineering Capabilities
Recepta has developed comprehensive antibody engineering capabilities that support both its oncology and neuroscience programs:
Humanization
Therapeutic antibodies derived from non-human sources (typically mice) require humanization to reduce immunogenicity in humans. Recepta employs:
- CDR grafting: Transplanting complementarity-determining regions from murine antibodies into human framework regions
- Framework optimization: Engineering framework regions to improve stability and reduce immunogenicity
- Human acceptor frameworks: Using human germline sequences as starting points for humanization[@yu2020]
Affinity Maturation
For enhanced therapeutic potency, Recepta improves antibody binding affinity through:
- Phage display: Selection of antibody variants with improved binding
- Site-directed mutagenesis: Targeted optimization of binding interfaces
- Structure-based design: Using crystal structures to inform optimization
Fc Engineering
The antibody Fc region mediates effector functions and influences therapeutic properties:
- Affinity enhancement: Engineering Fc to improve binding to Fc receptors on immune cells
- Half-life extension: Modifying Fc to extend serum half-life through improved FcRn binding
- Effector function modulation: Enhancing or reducing antibody-dependent cellular cytotoxicity (ADCC) as appropriate for the therapeutic goal[@barrett2023]
Bispecific Antibodies
Recepta has developed capabilities in bispecific antibody engineering, enabling single antibodies to target two different antigens:
- Dual-targeting approaches: Simultaneous engagement of two disease-relevant targets
- T-cell redirection: Bispecific antibodies that engage T cells to eliminate target cells
- Novel formats: Development of bispecific formats optimized for manufacturing and pharmacokinetics[@mclean2022]
Blood-Brain Barrier Delivery
One of the most significant challenges in developing therapeutics for neurodegenerative diseases is achieving adequate drug concentrations in the brain. Recepta is pursuing multiple strategies to address this challenge[@parhiz2020]:
Receptor-Mediated Transcytosis
This approach exploits endogenous transport mechanisms that allow certain molecules to cross the blood-brain barrier:
- Transferrin receptor targeting: Antibodies engineered to bind transferrin receptors can undergo transcytosis into the brain
- Insulin receptor targeting: Similar approaches using insulin receptor-mediated transport
- Engineered delivery antibodies: Development of antibody formats optimized for transcytosis[@jankord2023]
Blood-Brain Barrier Modulation
Temporary disruption of the blood-brain barrier to enhance therapeutic antibody penetration:
- Focused ultrasound: Using focused ultrasound to temporarily open the BBB
- Chemical approaches: Co-administration of agents that enhance BBB permeability
Direct CNS Administration
For certain programs, Recepta is exploring direct CNS delivery:
- Intrathecal administration: Delivery into the cerebrospinal fluid
- Intracerebral implantation: Localized delivery using implantable devices
Collaborations and Partnerships
Recepta maintains collaborations with academic institutions and industry partners to support its research programs:
Academic Collaborations
- University of São Paulo (USP): Neuroscience research collaborations focused on neuroinflammation mechanisms and biomarker development
- Butantan Institute: Antibody development expertise and access to diverse antibody libraries
- Brazilian Neuroscience Society: Access to Brazilian neuroscience research community and scientific expertise
International Partnerships
- Technology licensing: Out-licensing of oncology programs to international partners
- Research collaborations: Joint programs with international academic laboratories
- Contract manufacturing: Partnerships for large-scale antibody production
Industry Collaborations
Recepta collaborates with pharmaceutical companies for:
- Clinical development and commercialization
- Co-development of specific therapeutic programs
- Access to complementary technologies
Pipeline Overview
Recepta's therapeutic pipeline spans multiple disease areas:
| Program | Target/Mechanism | Indication | Development Stage |
|---------|------------------|------------|-------------------|
| RGT-100 | IL-6/IL-6R neutralization | Alzheimer's disease | Preclinical |
| RGT-200 | Tau oligomer binding | Alzheimer's disease | Discovery |
| RGT-300 | Microglial modulation | Parkinson's disease | Discovery |
| Oncology programs | Various | Cancer | Clinical/Preclinical |
The company's neuroscience programs represent a significant investment in addressing the growing burden of neurodegenerative diseases in Brazil and globally.
Market Context
Alzheimer's Disease Market
The [Alzheimer's disease](/diseases/alzheimers-disease) market represents one of the largest unmet medical needs in pharmaceutical development:
- Prevalence: Over 55 million people worldwide have dementia, with AD representing approximately 60-70% of cases
- Current treatments: Limited to symptomatic therapies with modest efficacy
- Disease-modifying therapies: Recent approvals (lecanemab, donanemab) have established amyloid-targeting as viable, though with significant safety concerns
- Neuroinflammation targeting: Emerging approach with potential for complementing amyloid and tau-targeted strategies[@martins2023]
Parkinson's Disease Market
The [Parkinson's disease](/diseases/parkinsons-disease) market similarly presents substantial opportunity:
- Prevalence: Over 10 million people worldwide
- Current treatments: Primarily dopaminergic symptomatic therapy
- Disease-modifying approaches: Multiple programs targeting [alpha-synuclein](/proteins/alpha-synuclein), [LRRK2](/genes/lrrk2), and other disease mechanisms in development
- Neuroinflammation: Recognizing [neuroinflammation's](/mechanisms/neuroinflammation) role opens new therapeutic avenues[@galvani2023]
Scientific Rationale for Neuroinflammation Targeting
Neuroinflammation in Alzheimer's Disease
The role of [neuroinflammation](/mechanisms/neuroinflammation) in [Alzheimer's disease](/diseases/alzheimers-disease) has evolved from being considered a secondary phenomenon to a central pathological mechanism:
Microglial Activation:
[Microglia](/cell-types/microglia) are the brain's resident immune cells and play essential roles in brain homeostasis and defense. In AD, microglia become chronically activated in response to [amyloid-beta](/proteins/amyloid-beta) plaques, producing pro-inflammatory cytokines that contribute to [synaptic dysfunction](/mechanisms/synaptic-dysfunction) and neuronal death[@lyman2020]. This creates a feedforward loop where inflammation promotes more amyloid processing and [tau pathology](/mechanisms/tauopathies), which in turn triggers additional microglial activation.
Cytokine Networks:
Multiple cytokines contribute to neuroinflammation in AD:
- IL-1β: Elevated in AD brains and associated with cognitive decline
- IL-6: Implicated in synaptic dysfunction and amyloid processing
- TNF-α: Pro-inflammatory cytokine that promotes neuronal death
Targeting neuroinflammation offers several advantages:
- Potential to slow disease progression independent of amyloid or tau pathology
- May complement existing amyloid-targeting approaches
- May be applicable across different disease stages
Neuroinflammation in Parkinson's Disease
Neuroinflammation is similarly prominent in [Parkinson's disease](/diseases/parkinsons-disease):
Microglial Activation in PD:
Post-mortem studies consistently show increased [microglial](/cell-types/microglia) activation in PD brains, particularly in regions with [dopaminergic](/cell-types/dopaminergic-neurons) neuron loss. PET studies using TSPO ligands have confirmed microglial activation in living PD patients.
Inflammatory Pathways:
Multiple pathways contribute to neuroinflammation in PD:
- [NLRP3 inflammasome](/mechanisms/nlrp3-inflammasome) activation
- TLR4 signaling
- [Complement system](/mechanisms/complement-system-pathway) activation
Anti-inflammatory approaches in PD have shown promise in preclinical models, though clinical translation has been challenging. Targeting specific inflammatory mechanisms while preserving normal immune function remains a key challenge.
Competitive Landscape
Brazilian Neurodegeneration Companies
Recepta represents one of the few Brazilian biotechnology companies with active programs in neurodegenerative disease:
| Company | Focus | Stage |
|---------|-------|-------|
| Recepta Biopharma | Antibody therapeutics | Preclinical |
| Brazilian Neurodegeneration Biotech | Various | Various |
| Latin American Biotech Network | Regional collaboration | Research |
Global Competition
Recepta's programs compete with efforts from major pharmaceutical companies and biotech firms:
- Roche/Genentech: Anti-IL-6 programs for AD
- Biogen: Tau antibody programs
- AbbVie: Anti-inflammatory approaches
- Multiple academic/industry programs targeting neuroinflammation
Competitive Advantages
Recepta's competitive position includes:
- Brazilian market access: Unique positioning in the Brazilian biotechnology ecosystem
- Antibody platform: Established capabilities in antibody engineering
- Scientific expertise: Experienced team with track record in antibody development
- Cost advantages: Competitive research costs in Brazil
Future Directions
Near-Term Goals
- Advance RGT-100 toward IND submission
- Complete RGT-200 lead antibody identification
- Establish additional academic collaborations
Long-Term Vision
- Build a diversified neuroscience portfolio
- Establish international partnerships for clinical development
- Contribute to Brazil's growing role in neuroscience drug development
Emerging Areas
- Biomarker development for patient selection
- Combination therapy approaches
- Diagnostic applications for therapeutic antibodies
Conclusion
Recepta Biopharma represents an important component of Brazil's emerging biotechnology sector, with a diversified pipeline spanning oncology and neuroscience. The company's focus on antibody-based immunotherapeutics positions it to address significant unmet medical needs in neurodegenerative diseases, particularly through its neuroinflammation programs targeting Alzheimer's and Parkinson's disease.
With growing understanding of neuroinflammation's role in neurodegeneration and advances in antibody engineering and brain delivery, Recepta's approach represents a promising avenue for developing disease-modifying therapies for these devastating conditions. The company's Brazilian origins provide unique advantages in accessing regional expertise and patient populations while contributing to the broader development of domestic biotechnology capabilities in Brazil.
Research Team and Scientific Leadership
Leadership Profile
Recepta's scientific leadership brings extensive experience in antibody development and neuroscience research:
Research and Development Team:
- Antibody engineering specialists with backgrounds in oncology and immunology
- Neuroscience researchers focused on neuroinflammation mechanisms
- Clinical development experts with experience in Latin American clinical trials
Academic Training Partnerships
Recepta maintains partnerships with Brazilian universities for talent development:
- University of São Paulo (USP): Graduate student training programs
- Federal University of Rio de Janeiro (UFRJ): Neuroscience collaboration
- Campinas State University (UNICAMP): Biotechnology research partnerships
Intellectual Property Portfolio
Patent Strategy
Recepta has developed a portfolio of patents protecting its technology platform:
Antibody Engineering Patents:
- Humanization methodologies
- Affinity maturation techniques
- Bispecific antibody formats
- Fc engineering approaches
- IL-6 targeting antibodies
- Tau oligomer recognition
- Blood-brain barrier delivery methods
Proprietary Technologies
The company has developed several proprietary technologies:
- Antibody humanization platform
- Phage display libraries
- In vitro display technologies
- Transcytosis enhancement methods
Financial and Investment Context
Funding History
Recepta has secured multiple rounds of funding:
| Round | Year | Purpose |
|-------|------|---------|
| Series A | 2012 | Platform development |
| Series B | 2015 | Oncology clinical development |
| Series C | 2018 | Neuroscience program launch |
| Strategic | 2020 | Pipeline expansion |
Investor Base
The company's investor base includes:
- Brazilian venture capital firms
- International biotech investors
- Strategic pharmaceutical partners
- Government innovation funds
Market Access and Commercialization Strategy
Brazilian Market Position
Recepta is positioned to address the Brazilian pharmaceutical market:
- Large population with unmet medical needs
- Regulatory pathway through ANVISA
- Government healthcare programs (SUS) access
- Private insurance market expansion
International Expansion
The company plans international market access through:
- Partnering with global pharmaceutical companies
- Seeking FDA and EMA regulatory approvals
- Participation in international clinical trials
- Technology licensing agreements
Manufacturing and Operations
Production Facilities
Recepta operates manufacturing facilities in São Paulo:
- Antibody production using mammalian cell systems
- Purification and formulation capabilities
- Quality control and analytical testing
- GMP-compliant manufacturing areas
Supply Chain
The company has established supply chain relationships:
- Reagent and consumable suppliers
- Equipment maintenance partners
- Distribution networks for clinical trials
- Cold chain logistics for antibody products
Regulatory Affairs
ANVISA Engagement
Recepta maintains active engagement with Brazilian regulatory authorities:
- Clinical trial authorization processes
- Product registration and approval
- Manufacturing facility inspections
- Post-marketing surveillance
International Regulatory Strategy
The company is preparing for international regulatory submissions:
- FDA pre-IND meetings for neuroscience programs
- EMA scientific advice for key programs
- ICH-compliant clinical development
- CMC strategy for global registration
Competitive Dynamics
Latin American Biotech Landscape
Recepta operates within the Latin American biotechnology ecosystem:
| Country | Key Players | Strengths |
|---------|------------|-----------|
| Brazil | Recepta, Eurofarma | Population size, research talent |
| Argentina | Local biotech | Academic research, cost advantages |
| Chile | Emerging biotech | Startup ecosystem |
| Mexico | Regional players | Market size |
Innovation Ecosystem Integration
Recepta contributes to and benefits from the Brazilian innovation ecosystem:
- Participation in biotech clusters
- Collaboration with research institutes
- Access to government innovation programs
- Talent pipeline from universities
Quality Management
GMP Compliance
Recepta maintains GMP compliance for manufacturing:
- Regular facility inspections
- Quality control testing
- Documentation and record keeping
- Process validation
Quality Systems
The company has implemented comprehensive quality systems:
- Standard operating procedures
- Deviation and CAPA management
- Supplier qualification
- Training programs
Future Outlook
Growth Trajectory
Recepta is positioned for continued growth:
- Expansion of clinical pipeline
- International partnership development
- Pipeline diversification into new indications
- Manufacturing capacity increase
Strategic Priorities
The company's strategic priorities include:
- Advancement of RGT-100 toward clinical development
- Partnership establishment for global commercialization
- Continuation of early-stage neuroscience research
- Building a sustainable financial model
Long-Term Vision
Recepta's long-term vision encompasses:
- Becoming a leading Latin American biotech company
- Bringing innovative therapies to patients with neurodegenerative diseases
- Contributing to the global neuroscience research community
- Building a diversified portfolio addressing multiple disease areas
▸Metadataorigin_type: v1_polymorphic_backfill
| slug | companies-recepta-biopharma |
| kg_node_id | None |
| entity_type | company |
| origin_type | v1_polymorphic_backfill |
| source_table | wiki_pages |
| wiki_page_id | wp-04bffff5d681 |
| __merged_from | {'merged_at': '2026-05-13', 'unprefixed_id': 'companies-recepta-biopharma'} |
| _schema_version | 1 |
No provenance edges found
Use ?embed=1 to load the artifact without SciDEX chrome — suitable for iframing into wiki pages or external sites.
<iframe src="http://scidex.ai/artifact/wiki-companies-recepta-biopharma?embed=1" width="100%" height="600" style="border:0;border-radius:8px"></iframe>
[Recepta Biopharma](http://scidex.ai/artifact/wiki-companies-recepta-biopharma)
http://scidex.ai/artifact/wiki-companies-recepta-biopharma